What is Amneal Pharmaceuticals Inc's earnings per share (EPS)?

Amneal Pharmaceuticals Inc (AMRX) reported diluted earnings per share of $0.22 for fiscal year 2025. This represents a 157.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Amneal Pharmaceuticals Inc Financials

AMRX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Amneal Pharmaceuticals Inc (AMRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 46/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Amneal Pharmaceuticals Inc has an operating margin of 13.1%, meaning the company retains $13 of operating profit per $100 of revenue. This results in a moderate score of 51/100, indicating healthy but not exceptional operating efficiency. This is up from 8.9% the prior year.

Growth

Amneal Pharmaceuticals Inc's revenue grew 8.0% year-over-year to $3.0B, a solid pace of expansion. This earns a growth score of 47/100.

Liquidity

Amneal Pharmaceuticals Inc's current ratio of 2.17 indicates adequate short-term liquidity, earning a score of 40/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Amneal Pharmaceuticals Inc has a free cash flow margin of 8.9%, earning a moderate score of 47/100. The company generates positive cash flow after capital investments, but with room for improvement.

Altman Z-Score Grey Zone

1.92

Amneal Pharmaceuticals Inc scores 1.92, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Piotroski F-Score Strong

7/9

Amneal Pharmaceuticals Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

4.72x

For every $1 of reported earnings, Amneal Pharmaceuticals Inc generates $4.72 in operating cash flow ($340.0M OCF vs $72.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$3.0B

YoY+8.0%

5Y CAGR+8.7%

Amneal Pharmaceuticals Inc generated $3.0B in revenue in fiscal year 2025. This represents an increase of 8.0% from the prior year.

EBITDA

$622.3M

YoY+27.0%

5Y CAGR+13.5%

Amneal Pharmaceuticals Inc's EBITDA was $622.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 27.0% from the prior year.

Net Income

$72.1M

YoY+161.6%

5Y CAGR+1.2%

Amneal Pharmaceuticals Inc reported $72.1M in net income in fiscal year 2025. This represents an increase of 161.6% from the prior year.

EPS (Diluted)

$0.22

YoY+157.9%

5Y CAGR-18.5%

Amneal Pharmaceuticals Inc earned $0.22 per diluted share (EPS) in fiscal year 2025. This represents an increase of 157.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$269.9M

YoY+11.0%

5Y CAGR-3.5%

Amneal Pharmaceuticals Inc generated $269.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 11.0% from the prior year.

Cash & Debt

$282.0M

YoY+155.1%

5Y CAGR-3.7%

Amneal Pharmaceuticals Inc held $282.0M in cash against $2.6B in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

315M

YoY+1.5%

Amneal Pharmaceuticals Inc had 315M shares outstanding in fiscal year 2025. This represents an increase of 1.5% from the prior year.

Margins & Returns

Gross Margin

36.9%

YoY+0.4pp

5Y CAGR+5.3pp

Amneal Pharmaceuticals Inc's gross margin was 36.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the prior year.

Operating Margin

13.1%

YoY+4.1pp

5Y CAGR+8.5pp

Amneal Pharmaceuticals Inc's operating margin was 13.1% in fiscal year 2025, reflecting core business profitability. This is up 4.1 percentage points from the prior year.

Net Margin

2.4%

YoY+6.6pp

5Y CAGR-1.0pp

Amneal Pharmaceuticals Inc's net profit margin was 2.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 6.6 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$186.2M

YoY-2.4%

5Y CAGR+0.7%

Amneal Pharmaceuticals Inc invested $186.2M in research and development in fiscal year 2025. This represents a decrease of 2.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$70.1M

YoY+34.9%

5Y CAGR+4.4%

Amneal Pharmaceuticals Inc invested $70.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 34.9% from the prior year.

AMRX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$3.0B+8.0%	$2.8B+16.7%	$2.4B+8.2%	$2.2B+5.7%	$2.1B+5.1%	$2.0B
Cost of Revenue	$1.9B+7.4%	$1.8B+12.7%	$1.6B+10.2%	$1.4B+7.8%	$1.3B-0.4%	$1.3B
Gross Profit	$1.1B+9.1%	$1.0B+24.4%	$820.6M+4.6%	$784.7M+2.0%	$769.0M+22.4%	$628.4M
R&D Expenses	$186.2M-2.4%	$190.7M+16.3%	$163.9M-16.2%	$195.7M-3.1%	$201.8M+12.2%	$179.9M
SG&A Expenses	$526.8M+10.6%	$476.4M+10.9%	$429.7M+7.5%	$399.7M+9.4%	$365.5M+11.9%	$326.7M
Operating Income	$394.1M+58.1%	$249.3M+22.0%	$204.4M+315.3%	-$94.9M-162.2%	$152.7M+67.5%	$91.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$11.3M-40.2%	$18.9M+123.2%	$8.5M+26.9%	$6.7M-40.5%	$11.2M+110.7%	-$104.4M
Net Income	$72.1M+161.6%	-$116.9M-39.2%	-$84.0M+69.0%	-$270.6M-2155.6%	$13.2M-80.6%	$67.8M
EPS (Diluted)	$0.22+157.9%	$-0.38+20.8%	$-0.48+44.2%	$-0.86-1328.6%	$0.07-88.5%	$0.61

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$814.3M+3.8%	$784.5M+8.3%	$724.5M+4.2%	$695.4M-4.8%	$730.5M+4.0%	$702.5M+0.1%	$701.8M+6.5%	$659.2M
Cost of Revenue	$517.1M+1.3%	$510.5M+16.5%	$438.3M-0.3%	$439.5M-6.0%	$467.6M+8.0%	$432.9M-4.2%	$451.8M+7.3%	$421.1M
Gross Profit	$297.2M+8.5%	$274.0M-4.3%	$286.3M+11.9%	$255.9M-2.7%	$262.9M-2.5%	$269.6M+7.8%	$249.9M+5.0%	$238.1M
R&D Expenses	$34.8M-45.0%	$63.4M+32.1%	$48.0M+19.8%	$40.0M-26.2%	$54.3M-11.2%	$61.1M+69.5%	$36.1M-8.3%	$39.3M
SG&A Expenses	$146.5M+6.3%	$137.8M+10.9%	$124.3M+5.1%	$118.3M-8.1%	$128.7M+8.4%	$118.7M+1.9%	$116.5M+3.4%	$112.6M
Operating Income	$112.0M+59.3%	$70.3M-36.8%	$111.4M+11.0%	$100.3M+32.4%	$75.8M-14.7%	$88.8M-7.0%	$95.5M+988.4%	-$10.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$5.7M+124.2%	-$23.4M-245.1%	$16.1M+25.1%	$12.9M+137.3%	$5.4M+47.9%	$3.7M+1.3%	$3.6M-41.2%	$6.2M
Net Income	$35.1M+1380.6%	$2.4M-89.4%	$22.4M+83.8%	$12.2M+139.2%	-$31.1M-19823.7%	-$156K-102.6%	$6.0M+106.5%	-$91.6M
EPS (Diluted)	N/A	$0.01-85.7%	$0.07+75.0%	$0.04	N/A	$0.00-100.0%	$0.02+106.7%	$-0.30

AMRX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$3.7B+5.1%	$3.5B+0.8%	$3.5B-8.6%	$3.8B-3.6%	$3.9B-1.7%	$4.0B
Current Assets	$1.9B+20.4%	$1.6B+15.2%	$1.4B-2.4%	$1.4B-7.1%	$1.5B-2.0%	$1.6B
Cash & Equivalents	$282.0M+155.1%	$110.6M+20.8%	$91.5M+252.4%	$26.0M-89.5%	$247.8M-27.4%	$341.4M
Inventory	$606.3M-1.0%	$612.5M+5.3%	$581.4M+9.5%	$530.7M+8.4%	$489.4M-0.3%	$490.6M
Accounts Receivable	N/A	N/A	N/A	$741.8M+12.0%	$662.6M+3.7%	$638.9M
Goodwill	$595.5M-0.3%	$597.4M-0.2%	$598.6M0.0%	$598.9M+1.0%	$593.0M+13.4%	$522.8M
Total Liabilities	$3.7B+3.8%	$3.6B+4.6%	$3.5B-1.4%	$3.5B-2.2%	$3.6B-3.3%	$3.7B
Current Liabilities	$881.6M-22.0%	$1.1B+33.4%	$846.6M+12.5%	$752.8M+11.2%	$677.2M+0.1%	$676.9M
Long-Term Debt	$2.6B+18.7%	$2.2B-9.4%	$2.4B-7.9%	$2.6B-3.3%	$2.7B-2.0%	$2.7B
Total Equity	-$70.8M+35.2%	-$109.3M-652.4%	$19.8M-93.4%	$298.4M-17.2%	$360.3M+18.8%	$303.3M
Retained Earnings	-$535.0M+11.9%	-$607.1M-23.8%	-$490.2M-20.7%	-$406.2M-47.1%	-$276.2M+3.7%	-$286.8M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$3.7B+2.2%	$3.6B+5.2%	$3.4B+1.7%	$3.4B-3.9%	$3.5B+1.2%	$3.5B-1.4%	$3.5B+1.5%	$3.5B
Current Assets	$1.9B+4.0%	$1.8B+16.0%	$1.6B+4.9%	$1.5B-4.9%	$1.6B+4.9%	$1.5B+1.9%	$1.5B+7.6%	$1.4B
Cash & Equivalents	$282.0M+40.1%	$201.2M+181.3%	$71.5M+20.9%	$59.2M-46.5%	$110.6M+49.4%	$74.0M+69.1%	$43.8M-5.9%	$46.5M
Inventory	$606.3M-1.3%	$614.5M+0.9%	$609.0M+1.3%	$601.4M-1.8%	$612.5M+2.7%	$596.4M+3.6%	$575.6M+0.9%	$570.7M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$595.5M-0.1%	$595.9M-0.2%	$597.4M0.0%	$597.5M0.0%	$597.4M-0.1%	$598.3M0.0%	$598.5M0.0%	$598.5M
Total Liabilities	$3.7B+1.1%	$3.7B+4.9%	$3.5B+1.1%	$3.5B-3.2%	$3.6B+1.6%	$3.6B-0.4%	$3.6B+1.3%	$3.5B
Current Liabilities	$881.6M+2.3%	$862.1M-22.1%	$1.1B+2.9%	$1.1B-4.8%	$1.1B+3.2%	$1.1B-1.7%	$1.1B+33.6%	$834.4M
Long-Term Debt	$2.6B-0.1%	$2.6B+19.6%	$2.1B-0.4%	$2.2B-0.4%	$2.2B-0.4%	$2.2B-0.4%	$2.2B-8.4%	$2.4B
Total Equity	-$70.8M+35.3%	-$109.5M+2.4%	-$112.1M+14.8%	-$131.7M-20.5%	-$109.3M-16.9%	-$93.4M-62.6%	-$57.5M+9.8%	-$63.7M
Retained Earnings	-$535.0M+6.2%	-$570.1M+0.4%	-$572.5M+3.8%	-$594.9M+2.0%	-$607.1M-5.4%	-$576.0M0.0%	-$575.8M+1.0%	-$581.8M

AMRX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$340.0M+15.2%	$295.1M-14.6%	$345.6M+430.8%	$65.1M-73.1%	$241.8M-36.2%	$379.0M
Capital Expenditures	$70.1M+34.9%	$51.9M+20.1%	$43.2M-6.9%	$46.4M-2.8%	$47.7M-15.4%	$56.4M
Free Cash Flow	$269.9M+11.0%	$243.2M-19.6%	$302.4M+1517.5%	$18.7M-90.4%	$194.1M-39.8%	$322.6M
Investing Cash Flow	-$112.3M-78.2%	-$63.0M+9.0%	-$69.2M+60.3%	-$174.3M+10.2%	-$194.2M+38.8%	-$317.5M
Financing Cash Flow	-$31.5M+85.1%	-$211.8M+0.4%	-$212.6M-99.4%	-$106.6M+22.8%	-$138.1M-204.8%	$131.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$130.3M+10.0%	$118.5M+41.3%	$83.8M+1031.5%	$7.4M-93.7%	$118.1M-16.7%	$141.8M+257.5%	$39.7M+999.3%	-$4.4M
Capital Expenditures	$21.8M+77.0%	$12.3M-46.1%	$22.8M+73.5%	$13.2M-13.2%	$15.2M-10.6%	$16.9M+59.5%	$10.6M+15.5%	$9.2M
Free Cash Flow	$108.5M+2.3%	$106.2M+74.1%	$61.0M+1159.9%	-$5.8M-105.6%	$102.9M-17.5%	$124.8M+330.0%	$29.0M+313.3%	-$13.6M
Investing Cash Flow	-$45.5M-102.3%	-$22.5M+15.4%	-$26.5M-49.2%	-$17.8M-10.8%	-$16.1M+22.5%	-$20.7M-220.4%	-$6.5M+67.3%	-$19.8M
Financing Cash Flow	-$10.1M-117.0%	$59.4M+242.6%	-$41.7M-6.4%	-$39.2M+36.0%	-$61.2M+33.7%	-$92.3M-163.2%	-$35.1M-51.5%	-$23.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AMRX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	36.9%+0.4pp	36.5%+2.2pp	34.3%-1.2pp	35.5%-1.3pp	36.7%+5.2pp	31.5%
Operating Margin	13.1%+4.1pp	8.9%+0.4pp	8.5%+12.8pp	-4.3%-11.6pp	7.3%+2.7pp	4.6%
Net Margin	2.4%+6.6pp	-4.2%-0.7pp	-3.5%+8.7pp	-12.2%-12.9pp	0.6%-2.8pp	3.4%
Return on Equity	N/A	N/A	-424.6%-333.9pp	-90.7%-94.3pp	3.6%-18.7pp	22.4%
Return on Assets	2.0%+5.3pp	-3.3%-0.9pp	-2.4%+4.7pp	-7.1%-7.4pp	0.3%-1.4pp	1.7%
Current Ratio	2.17+0.8	1.41-0.2	1.63-0.2	1.88-0.4	2.24-0.0	2.29
Debt-to-Equity	-36.23-16.4	-19.78-140.4	120.62+111.9	8.69+1.2	7.44-1.6	9.02
FCF Margin	8.9%+0.2pp	8.7%-3.9pp	12.6%+11.8pp	0.8%-8.4pp	9.3%-6.9pp	16.2%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	36.5%+1.6pp	34.9%-4.6pp	39.5%+2.7pp	36.8%+0.8pp	36.0%-2.4pp	38.4%+2.7pp	35.6%-0.5pp	36.1%
Operating Margin	13.8%+4.8pp	9.0%-6.4pp	15.4%+0.9pp	14.4%+4.1pp	10.4%-2.3pp	12.6%-1.0pp	13.6%+15.2pp	-1.6%
Net Margin	4.3%+4.0pp	0.3%-2.8pp	3.1%+1.3pp	1.8%+6.0pp	-4.3%-4.2pp	-0.0%-0.9pp	0.9%+14.8pp	-13.9%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	0.9%+0.9pp	0.1%-0.6pp	0.7%+0.3pp	0.4%+1.3pp	-0.9%-0.9pp	0.0%-0.2pp	0.2%+2.8pp	-2.6%
Current Ratio	2.17+0.0	2.13+0.7	1.43+0.0	1.400.0	1.41+0.0	1.38+0.0	1.33-0.3	1.65
Debt-to-Equity	-36.23-12.8	-23.45-4.3	-19.14-2.8	-16.36+3.4	-19.78+3.4	-23.22+14.7	-37.89-0.6	-37.31
FCF Margin	13.3%-0.2pp	13.5%+5.1pp	8.4%+9.3pp	-0.8%-14.9pp	14.1%-3.7pp	17.8%+13.6pp	4.1%+6.2pp	-2.1%

Note: Shareholder equity is negative (-$70.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Prestige Consmr Healthcare Inc PBH

$2.8B

Indivior Pharmaceuticals Inc. INDV

$3.5B

Perrigo Co Plc PRGO

$1.3B

Hutchmed (China) Limited HCM

$2.4B

Bausch Health Companies Inc BHC

$1.9B

Frequently Asked Questions

What is Amneal Pharmaceuticals Inc's annual revenue?

Amneal Pharmaceuticals Inc (AMRX) reported $3.0B in total revenue for fiscal year 2025. This represents a 8.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Amneal Pharmaceuticals Inc's revenue growing?

Amneal Pharmaceuticals Inc (AMRX) revenue grew by 8% year-over-year, from $2.8B to $3.0B in fiscal year 2025.

Is Amneal Pharmaceuticals Inc profitable?

Yes, Amneal Pharmaceuticals Inc (AMRX) reported a net income of $72.1M in fiscal year 2025, with a net profit margin of 2.4%.

What is Amneal Pharmaceuticals Inc's EBITDA?

Amneal Pharmaceuticals Inc (AMRX) had EBITDA of $622.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Amneal Pharmaceuticals Inc have?

As of fiscal year 2025, Amneal Pharmaceuticals Inc (AMRX) had $282.0M in cash and equivalents against $2.6B in long-term debt.

What is Amneal Pharmaceuticals Inc's gross margin?

Amneal Pharmaceuticals Inc (AMRX) had a gross margin of 36.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Amneal Pharmaceuticals Inc's operating margin?

Amneal Pharmaceuticals Inc (AMRX) had an operating margin of 13.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Amneal Pharmaceuticals Inc's net profit margin?

Amneal Pharmaceuticals Inc (AMRX) had a net profit margin of 2.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Amneal Pharmaceuticals Inc's free cash flow?

Amneal Pharmaceuticals Inc (AMRX) generated $269.9M in free cash flow during fiscal year 2025. This represents a 11.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Amneal Pharmaceuticals Inc's operating cash flow?

Amneal Pharmaceuticals Inc (AMRX) generated $340.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Amneal Pharmaceuticals Inc's total assets?

Amneal Pharmaceuticals Inc (AMRX) had $3.7B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Amneal Pharmaceuticals Inc's capital expenditures?

Amneal Pharmaceuticals Inc (AMRX) invested $70.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Amneal Pharmaceuticals Inc spend on research and development?

Amneal Pharmaceuticals Inc (AMRX) invested $186.2M in research and development during fiscal year 2025.

How many shares does Amneal Pharmaceuticals Inc have outstanding?

Amneal Pharmaceuticals Inc (AMRX) had 315M shares outstanding as of fiscal year 2025.

What is Amneal Pharmaceuticals Inc's current ratio?

Amneal Pharmaceuticals Inc (AMRX) had a current ratio of 2.17 as of fiscal year 2025, which is generally considered healthy.

What is Amneal Pharmaceuticals Inc's debt-to-equity ratio?

Amneal Pharmaceuticals Inc (AMRX) had a debt-to-equity ratio of -36.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Amneal Pharmaceuticals Inc's return on assets (ROA)?

Amneal Pharmaceuticals Inc (AMRX) had a return on assets of 2.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Why is Amneal Pharmaceuticals Inc's debt-to-equity ratio negative or unusual?

Amneal Pharmaceuticals Inc (AMRX) has negative shareholder equity of -$70.8M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Amneal Pharmaceuticals Inc's Altman Z-Score?

Amneal Pharmaceuticals Inc (AMRX) has an Altman Z-Score of 1.92, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Amneal Pharmaceuticals Inc's Piotroski F-Score?

Amneal Pharmaceuticals Inc (AMRX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Amneal Pharmaceuticals Inc's earnings high quality?

Amneal Pharmaceuticals Inc (AMRX) has an earnings quality ratio of 4.72x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Amneal Pharmaceuticals Inc?

Amneal Pharmaceuticals Inc (AMRX) scores 46 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.